CUV ASX News

22 December 2024

Health Canada validates SCENESSE New Drug Submission

Health Canada validates CLINUVEL's SCENESSE® for EPP treatment review.

CLINUVEL Pharmaceuticals SCENESSE® Health Canada EPP Treatment Stock Market News

Posted on: 22/12/2024

4 December 2024

Chair's letter to Shareholders

CLINUVEL highlights strategic growth and financial resilience despite share price volatility.

CLINUVEL Pharmaceuticals Stock Market News Biotechnology Financial Strategy Clinical Trials

Posted on: 04/12/2024

19 November 2024

SCENESSE dosage expansion under review by EMA

CLINUVEL aims to increase SCENESSE® dosage for EPP patients in Europe.

CLINUVEL SCENESSE® EPP Pharmaceuticals EMA Approval

Posted on: 19/11/2024

17 November 2024

CLINUVEL prioritises three strategic programs

CLINUVEL prioritizes vitiligo, ACTH, and porphyrias, suspending other projects.

CLINUVEL Clinical Programs Pharmaceuticals Stock Market News Healthcare

Posted on: 17/11/2024

30 September 2024

Canadian New Drug Submission for SCENESSE in EPP filed

CLINUVEL seeks Health Canada approval for SCENESSE® to treat EPP.

CLINUVEL SCENESSE® Health Canada EPP Stock Market News Pharmaceuticals

Posted on: 30/09/2024